| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.27 | 1e-05 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.26 | 1e-05 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.24 | 8e-05 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | 0.26 | 0.002 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.17 | 0.007 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.007 |